Jul. 17, 2012
July 18, 2012. Tianjin International Joint Academy of Biotechnology and Medicine (TJAB) has formed a JV with Antisense Technologies of Australia (ANP) to develop a drug discovered by ANP. The drug, ATL1102, is aimed at multiple sclerosis, stem cell mobilization and asthma.
TJAB will be responsible for commercialization of ATL1102 in China and Hong Kong, while ANP will be responsible for its commercialization in the rest of the world.